While there is nothing regarding the 700 mg group,
Post# of 147852
“The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant. Leronlimab compared to placebo also reached near significance for the secondary endpoint cT1. ”
This is different from the historical control group data discussed by Nader/Recknor previously.
I think this bodes very well for what we will see from 700 mg data.